Skip to content
PubMed This is a summary of 82 peer-reviewed journal articles Updated
Endocrinology · Primary Pigmented Nodular Adrenocortical Disease

Primary Pigmented Nodular Adrenocortical Disease (PPNAD): A Patient Guide

At a Glance

PPNAD is a rare condition in which tiny adrenal nodules cause cortisol excess that can come and go, so scans may look normal. Repeated hormone testing can support diagnosis, and removing both adrenal glands controls cortisol but requires lifelong hormone replacement and adrenal-crisis planning.

Primary Pigmented Nodular Adrenocortical Disease (PPNAD) is an exceptionally rare and complex condition that causes the adrenal glands to overproduce the hormone cortisol. Cushing’s syndrome is the general term for cortisol excess and can have many causes, including exposure to prescribed steroid medications. Unlike some endogenous forms of Cushing’s syndrome—such as Cushing’s disease, which is driven by a pituitary tumor in the brain—PPNAD is ACTH-independent [1]. This means the adrenal glands act on their own without external signals.

The condition is characterized by the development of multiple tiny, dark-colored nodules within the adrenal glands. Because these nodules are often only a few millimeters in size, they can be difficult to detect on standard imaging like CT or MRI scans, which frequently appear entirely normal despite severe hormonal imbalances [2][3].

The behavior of PPNAD is often “quiet” or cyclic, meaning cortisol levels may rise and fall in waves rather than staying constantly high [4]. This makes the diagnostic journey challenging, as standard hormone tests may occasionally return normal results even when the disease is present. Diagnosis requires a high index of clinical suspicion and repeated biochemical testing guided by an endocrinologist. In selected cases, specialists may use multi-day dexamethasone testing (such as the Liddle test), which can reveal a paradoxical rise in cortisol levels that may support the diagnosis in certain clinical contexts [5][6].

In many cases, PPNAD is the first sign of a broader genetic syndrome known as Carney Complex [7]. This connection is typically driven by a pathogenic germline mutation in the PRKAR1A gene [8]. Because this mutation can affect various tissues throughout the body, PPNAD is often considered a multi-system issue that requires a holistic approach to care. This includes looking beyond the adrenal glands to monitor other potential manifestations, most notably non-cancerous heart tumors called cardiac myxomas [9][10].

The standard of care for resolving the cortisol excess in PPNAD is a bilateral adrenalectomy, or the surgical removal of both adrenal glands [11]. While this surgery is a definitive cure for the hypercortisolism, it marks the beginning of a new phase of life centered on survivorship and careful management. Following surgery, patients must take lifelong hormone replacement medications to perform the functions the adrenal glands once handled. This requires a dedicated commitment to daily dosing and a deep understanding of how to prevent adrenal crisis during times of physical stress or illness [12][13].

Ultimately, living with PPNAD is a journey of vigilance and partnership with a specialized medical team. By combining consistent hormone replacement therapy with individualized screenings for other features of Carney Complex, patients can effectively manage the risks associated with the disease [14][15].

Common questions in this guide

What is primary pigmented nodular adrenocortical disease?
PPNAD is a rare condition in which multiple tiny, dark-colored nodules in the adrenal glands make too much cortisol. It is a form of cortisol excess in which the adrenal glands act independently of the usual pituitary signal.
Can I have PPNAD if my CT or MRI scan looks normal?
Yes. The nodules can be only a few millimeters wide, so CT and MRI scans often look normal even when cortisol production is abnormal. Doctors may use repeated hormone testing to investigate PPNAD.
Why can hormone tests sometimes miss PPNAD?
PPNAD may be cyclic, meaning cortisol levels rise and fall rather than remaining high. A single test can therefore be normal, and an endocrinologist may recommend repeated testing or, in selected cases, a multi-day dexamethasone test.
Is PPNAD connected to Carney Complex?
PPNAD is often the first sign of Carney Complex, a genetic syndrome that can affect several parts of the body. A disease-causing change in the PRKAR1A gene is commonly involved, so genetic counseling and screening for related findings, including heart myxomas, may be discussed.
What should I expect after surgery to remove both adrenal glands?
Removing both adrenal glands is the definitive treatment for PPNAD-related cortisol excess, but the body can no longer make its usual adrenal hormones. Lifelong hormone replacement and a clear plan for illness or physical stress are needed to reduce the risk of adrenal crisis.
Which specialists may be involved in PPNAD care?
An endocrinologist can guide cortisol testing and hormone replacement, while a genetics professional can assess Carney Complex and PRKAR1A-related risk. A cardiologist may help monitor for cardiac myxomas, and a surgical team may manage bilateral adrenalectomy.

Get notified when new evidence is published on pigmented nodular adrenocortical disease, primary, 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (15)
  1. 1

    ACTH independent Cushing's syndrome: Diagnosis and etiology.

    Ortiz-Flores AE

    Vitamins and hormones 2026; (132()):79-92 doi:10.1016/bs.vh.2026.02.001.

    PMID: 42236016
  2. 2

    Bilateral Adrenocortical Nodular Disease and Cushing's Syndrome.

    Bouys L, Violon F, Louiset E, et al.

    The Journal of clinical endocrinology and metabolism 2024; (109(10)):2422-2432 doi:10.1210/clinem/dgae419.

    PMID: 38888184
  3. 3

    Challenging Diagnostic Workup of a 22-year-old Patient With Primary Pigmented Nodular Adrenocortical Disease.

    Wernig J, Pilz S, Trummer C, et al.

    JCEM case reports 2024; (2(10)):luae174 doi:10.1210/jcemcr/luae174.

    PMID: 39355138
  4. 4

    Integrated clinical-genetic-pathological analysis expands the phenotypic and molecular spectrum of PPNAD across carney complex and isolated forms.

    Kuhn AW, Lerario AM, Charchar HL, et al.

    European journal of endocrinology 2026; (195(2)):217-228 doi:10.1093/ejendo/lvag137.

    PMID: 42543523
  5. 5

    Efficacy of dexamethasone suppression test during the diagnosis of primary pigmented nodular adrenocortical disease in Chinese adrenocorticotropic hormone-independent Cushing syndrome.

    Chen S, Li R, Lu L, et al.

    Endocrine 2018; (59(1)):183-190 doi:10.1007/s12020-017-1436-9.

    PMID: 29094256
  6. 6

    Update on primary micronodular bilateral adrenocortical diseases.

    Maillet M, Bourdeau I, Lacroix A

    Current opinion in endocrinology, diabetes, and obesity 2020; (27(3)):132-139 doi:10.1097/MED.0000000000000538.

    PMID: 32209819
  7. 7

    The clinical characteristics and pathogenic variants of primary pigmented nodular adrenocortical disease in 210 patients: a systematic review.

    Sun J, Ding L, He L, et al.

    Frontiers in endocrinology 2024; (15()):1356870 doi:10.3389/fendo.2024.1356870.

    PMID: 39006359
  8. 8

    Genetics of micronodular adrenal hyperplasia and Carney complex.

    Tirosh A, Valdés N, Stratakis CA

    Presse medicale (Paris, France : 1983) 2018; (47(7-8 Pt 2)):e127-e137 doi:10.1016/j.lpm.2018.07.005.

    PMID: 30093212
  9. 9

    Frequency and Incidence of Carney Complex Manifestations: A Prospective Multicenter Study With a Three-Year Follow-Up.

    Espiard S, Vantyghem MC, Assié G, et al.

    The Journal of clinical endocrinology and metabolism 2020; (105(3)) doi:10.1210/clinem/dgaa002.

    PMID: 31912137
  10. 10

    Recurrent left atrial myxoma in Carney complex: A case report of a familial pedigree.

    Wang L, Wang Q, Zhou Y, et al.

    Medicine 2018; (97(12)):e0247 doi:10.1097/MD.0000000000010247.

    PMID: 29561454
  11. 11

    Cushing´s syndrome due to bilateral adrenal cortical disease: Bilateral macronodular adrenal cortical disease and bilateral micronodular adrenal cortical disease.

    Araujo-Castro M, Marazuela M

    Frontiers in endocrinology 2022; (13()):913253 doi:10.3389/fendo.2022.913253.

    PMID: 35992106
  12. 12

    PRKAR1A-negative familial Cushing's syndrome: two case reports.

    Lim LL, Kitan N, Paramasivam SS, et al.

    Journal of medical case reports 2015; (9()):277 doi:10.1186/s13256-015-0757-7.

    PMID: 26619967
  13. 13

    Perioperative Risks and Long-Term Outcomes of Bilateral Adrenalectomy: A Multicenter Retrospective Cohort Study Across Cushing's Syndrome and Non-Cushing Etiologies.

    Güngör Semiz G, Yılmaz N, Aydemir M, et al.

    Medicina (Kaunas, Lithuania) 2026; (62(7)) doi:10.3390/medicina62071373.

    PMID: 42512915
  14. 14

    Cushing's syndrome due to primary pigmented nodular adrenal disease in two brothers with Carney complex.

    Attri B, Aggarwal A, Mattoo S, Kulshreshtha B

    Pediatric endocrinology, diabetes, and metabolism 2020; (26(3)):155-158 doi:10.5114/pedm.2020.95625.

    PMID: 32901471
  15. 15

    PRIMARY PIGMENTED NODULAR ADRENOCORTICAL DISEASE (PPNAD) PRESENTING AS CUSHING SYNDROME IN A CHILD AND REVIEW OF LITERATURE.

    Bavadiya G, Roy A, Sarkar KK, et al.

    Acta endocrinologica (Bucharest, Romania : 2005) 2020; (16(3)):362-365 doi:10.4183/aeb.2020.362.

    PMID: 33363661

This page is for informational purposes only and does not constitute medical advice. It cannot replace personalized guidance from an endocrinologist, surgeon, genetic counselor, or other clinician about PPNAD and hormone replacement.